Dataset Viewer
Auto-converted to Parquet Duplicate
slug
large_stringlengths
3
19
name
large_stringlengths
6
57
source_index
int64
0
9
source_text
large_stringlengths
76
356
doi
large_stringlengths
13
34
resolved
large_stringclasses
1 value
verified_title
large_stringlengths
24
202
5-amino-1mq
5-Amino-1MQ (NNMT inhibitor)
0
Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258-262 (target validation; genetic, not 5A1MQ).
10.1038/nature13198
high
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
adipotide
Adipotide (FTPP / Prohibitin-TP01)
0
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625-632 (PMID 15133506) — the foundational paper.
10.1038/nm1048
high
Reversal of obesity by targeted ablation of adipose tissue
adipotide
Adipotide (FTPP / Prohibitin-TP01)
1
Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011 (the ~11%/28-day primate result + renal-tubular signal).
10.1126/scitranslmed.3002621
high
A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
adipotide
Adipotide (FTPP / Prohibitin-TP01)
2
Rupnick MA, et al. Adipose tissue mass can be regulated through the vasculature. PNAS. 2002 (proof-of-concept).
10.1073/pnas.162349799
high
Adipose tissue mass can be regulated through the vasculature
afamelanotide
Afamelanotide (Scenesse / Melanotan-1)
3
Wensink D, et al. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021 (review).
10.1080/17512433.2021.1879638
high
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
ahk-cu
AHK-Cu (Copper Tripeptide-3)
0
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834–839. (PMID 17703734) — the foundational ex-vivo/in-vitro study.
10.1007/bf02978833
high
The effect of tripeptide-copper complex on human hair growth in vitro
aicar
AICAR (Acadesine)
0
Narkar VA, et al. AMPK and PPARδ Agonists Are Exercise Mimetics. Cell. 2008;134:405-415 (the ~44% endurance / "exercise mimetic" paper; Evans lab, Salk).
10.1016/j.cell.2008.06.051
high
AMPK and PPARδ Agonists Are Exercise Mimetics
alpha-arbutin
Alpha Arbutin
0
Tantanasrigul P, Sripha A, Chongmelaxme B. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study. J Cosmet Dermatol. 2024;e16562.
10.1111/jocd.16562
high
The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study
alpha-arbutin
Alpha Arbutin
1
Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Inhibitory Effects of Alpha-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model. Biol Pharm Bull. 2004;27(4):510-514.
10.1248/bpb.27.510
high
Inhibitory Effects of Alpha-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model
alpha-arbutin
Alpha Arbutin
2
Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel). 2021;10(7):1129.
10.3390/antiox10071129
high
Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties
amycretin
Amycretin
1
Dahl K, et al. Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: a Phase 1b/2a study. Lancet. 2025.
10.1016/s0140-6736(25)01185-7
high
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
argireline
Argireline (Acetyl Hexapeptide-8)
0
Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002.
10.1046/j.1467-2494.2002.00153.x
high
A synthetic hexapeptide (Argireline) with antiwrinkle activity
argireline
Argireline (Acetyl Hexapeptide-8)
3
Lim S-H, et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. (penetration limits.) PMC5785486.
10.1038/s41598-017-18454-z
high
Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification
argireline
Argireline (Acetyl Hexapeptide-8)
4
Public interest in acetyl hexapeptide-8: longitudinal analysis. PMC10915729.
10.2196/54217
high
Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis
azelaic-acid
Azelaic Acid
0
King S, Campbell J, Rowe R, Daly ML, Moncrieff G, Maybury C. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. J Cosmet Dermatol. 2023;22(10):2650-2662.
10.1111/jocd.15923
high
A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging
azelaic-acid
Azelaic Acid
1
Albzea W, AlRashidi R, Alkandari D, et al. Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(7):e41796.
10.7759/cureus.41796
high
Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials
azelaic-acid
Azelaic Acid
2
McKesey J, Tovar-Garza A, Pandya AG. Melasma Treatment: An Evidence-Based Review. Am J Clin Dermatol. 2020;21(2):173-225.
10.1007/s40257-019-00488-w
high
Melasma Treatment: An Evidence-Based Review
bakuchiol
Bakuchiol
0
Chaudhuri RK, Bojanowski K. Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti- aging effects. Int J Cosmet Sci. 2014; 36(3):221-30. doi:10.1111/ics.12117. [Sytheon Ltd — declared conflict of interest]
10.1111/ics.12117
high
Bakuchiol: a retinol‐like functional compound revealed by gene expression profiling and clinically proven to have anti‐aging effects
bakuchiol
Bakuchiol
1
Dhaliwal S, Rybak I, Ellis SR, et al. Prospective, randomized, double- blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019; 180(2):289-296. doi:10.1111/bjd.16918. [Independent — University of California / Michigan / Florida / Pennsylvania]
10.1111/bjd.16918
high
Prospective, randomized, double‐blind assessment of topical bakuchiol and retinol for facial photoageing
bakuchiol
Bakuchiol
2
Draelos ZD, Gunt H, Zeichner J, Levy S. Clinical evaluation of a nature- based bakuchiol anti-aging moisturizer for sensitive skin. J Drugs Dermatol. 2020; 19(12):1181.
10.36849/jdd.2020.5522
high
Clinical Evaluation of a Nature-Based Bakuchiol Anti-Aging Moisturizer for Sensitive Skin
bakuchiol
Bakuchiol
3
Goldberg DJ, Robinson DM, Granger C. Clinical evidence of the efficacy and safety of a new 3-in-1 anti-aging topical night serum-in-oil containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate. J Cosmet Dermatol. 2020.
10.1111/jocd.12896
high
Clinical evidence of the efficacy and safety of a new 3‐in‐1 anti‐aging topical night serum‐in‐oil containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate: 103 females treated from 28 to 84 days
bakuchiol
Bakuchiol
6
Chaudhuri RK. Chapter — Bakuchiol: A Retinol-Like Functional Compound, Modulating Multiple Retinol and Non-Retinol Targets. In: Cosmeceuticals and Active Cosmetics. 2015. [Sytheon — mechanistic review]
10.1201/b18895-2
high
Bakuchiol: A Retinol-Like Functional Compound, Modulating Multiple Retinol and Non-Retinol Targets
bimagrumab
Bimagrumab (BYM338)
0
Heymsfield SB, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type-2 diabetes and obesity: a Phase 2 randomized clinical trial. JAMA Netw Open. 2021.
10.1001/jamanetworkopen.2020.33457
high
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
bimagrumab
Bimagrumab (BYM338)
2
Nunn E, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024.
10.1016/j.molmet.2024.101880
high
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
bpc-157
BPC-157
1
Chang C-H, et al. Pentadecapeptide BPC 157 enhances growth-hormone-receptor expression in tendon fibroblasts. 2014.
10.3390/molecules191119066
high
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
bpc-157
BPC-157
2
Hsieh M-J, et al. Therapeutic potential of pro-angiogenic BPC157 associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017.
10.1007/s00109-016-1488-y
high
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
bpc-157
BPC-157
4
Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: a Systematic Review. 2025. — 544 articles screened → 36 included (35 preclinical, 1 clinical).
10.1177/15563316251355551
high
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
ceramides
Ceramides
0
Elias PM, Wakefield JS. Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2014.
10.1016/j.jaci.2014.05.048
high
Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis
ceramides
Ceramides
1
Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014; 71(1):177-84.
10.1016/j.jaad.2014.01.891
high
The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products
ceramides
Ceramides
3
Spada F, Barnes TM, Greive KA. Skin hydration is significantly increased by a cream formulated to mimic the skin's own natural moisturizing systems. Clin Cosmet Investig Dermatol. 2018.
10.2147/ccid.s177697
high
Skin hydration is significantly increased by a cream formulated to mimic the skin’s own natural moisturizing systems
cerebrolysin
Cerebrolysin
0
Cochrane reviews — Cerebrolysin for vascular dementia (2013; updated 2025) and for acute ischemic stroke (2023, 7 RCTs / 1,773 participants: no mortality benefit; ↑ non-fatal serious AEs RR ~2.39).
10.1002/14651858.cd008900.pub2
high
Cerebrolysin for vascular dementia
dasatinib-quercetin
Dasatinib + Quercetin / Fisetin (Senolytics)
0
Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015 (D+Q discovery; SCAP hypothesis).
10.1111/acel.12344
high
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
dasatinib-quercetin
Dasatinib + Quercetin / Fisetin (Senolytics)
1
Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med 2020 (D, Q, Fisetin, Navitoclax as first senolytics).
10.1111/joim.13141
high
Senolytic drugs: from discovery to translation
dasatinib-quercetin
Dasatinib + Quercetin / Fisetin (Senolytics)
3
Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018 (top flavonoid; mouse lifespan).
10.1016/j.ebiom.2018.09.015
high
Fisetin is a senotherapeutic that extends health and lifespan
ectoin
Ectoin
0
Graf R, et al. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol. 2008; 26(4):326-33.
10.1016/j.clindermatol.2008.01.002
high
The multifunctional role of ectoine as a natural cell protectant
ectoin
Ectoin
1
Marini A, et al. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol. 2014.
10.1159/000351381
high
Ectoine-Containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis: A Randomised, Comparator-Controlled, Intra-Individual Double-Blind, Multi-Center Trial
ectoin
Ectoin
3
Bilstein A, et al. Ectoin in the Treatment of Irritations and Inflammations of the Eye Surface. Biomed Res Int. 2021.
10.1155/2021/8885032
high
Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface
ectoin
Ectoin
4
Kauth M, Trusova O. Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review. Dermatol Ther (Heidelb). 2022.
10.1007/s13555-021-00676-9
high
Topical Ectoine Application in Children and Adults to Treat Inflammatory Diseases Associated with an Impaired Skin Barrier: A Systematic Review
epitalon
Epitalon (Epithalon)
0
Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003.
10.1023/a:1025493705728
high
Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells
epitalon
Epitalon (Epithalon)
2
Araj (et al.). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. (independent in-vitro study)
10.1007/s10522-025-10315-x
high
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
follistatin
Follistatin (FST-344)
2
Kota J, Sumner CJ, et al. Inhibition of myostatin, with emphasis on follistatin as a therapy for muscle disease. (Review; PMC2717722.)
10.1002/mus.21244
high
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
ghk-cu
GHK-Cu (Copper Tripeptide-1)
4
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide (gene-expression review). Int J Mol Sci. 2018 (PMID 29986520).
10.3390/ijms19071987
high
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
ghk-cu
GHK-Cu (Copper Tripeptide-1)
5
Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems, prospects. BioImpacts. 2024.
10.34172/bi.30071
high
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
ghrp-6
GHRP-6
2
Kojima M, Kangawa K, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. (the endogenous ligand GHRP-6 pointed to)
10.1038/45230
high
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
glutathione
Glutathione (GSH)
0
Sonthalia S, et al. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016 (mechanism, evidence, Philippine FDA warning).
10.4103/0378-6323.179088
high
Glutathione as a skin whitening agent: Facts, myths, evidence and controversies
glutathione
Glutathione (GSH)
1
Glutathione for skin lightening: a regnant myth or evidence-based verity? (PMC5808366) — oral GRAS status, low bioavailability, IV controversy.
10.5826/dpc.0801a04
high
Glutathione for skin lightening: a regnant myth or evidence-based verity?
hexarelin
Hexarelin (Examorelin)
0
Bodart V, Ong H, et al. CD36 mediates the cardiovascular action of growth-hormone-releasing peptides in the heart. Circ Res. 2002. (CD36 identification)
10.1161/01.res.0000016164.02525.b4
high
CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart
humanin
Humanin (HN / HNG / S14G-Humanin)
0
Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. PNAS. 2001 (original discovery).
10.1073/pnas.101133498
high
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ
hyaluronic-acid
Hyaluronic Acid (Sodium Hyaluronate)
2
Nobile V, et al. Oral intake and topical application of hyaluronic acid ameliorates skin aging signs: efficacy results of a placebo-controlled in&out trial. Cosmetics. 2025; 12:52.
10.3390/cosmetics12020052
high
Oral Intake and Topical Application of Hyaluronic Acid Ameliorates Skin Aging Signs: Efficacy Results of a Placebo-Controlled In&Out Trial
hyaluronic-acid
Hyaluronic Acid (Sodium Hyaluronate)
3
Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults. Sci Rep. 2025.
10.1038/s41598-025-32758-5
high
Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: a randomized, double-blind, placebo-controlled trial in 150 healthy adults
hyaluronic-acid
Hyaluronic Acid (Sodium Hyaluronate)
5
Zhang R, Yaqoubi M, et al. The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta-Analysis. J Cosmet Dermatol. 2024; PMC11731322.
10.1111/jocd.16760
high
The Effect of Local Hyaluronic Acid Injection on Skin Aging: A Systematic Review and Meta‐Analysis
ipamorelin
Ipamorelin
0
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. (PMID 9849822)
10.1530/eje.0.1390552
high
Ipamorelin, the first selective growth hormone secretagogue
ipamorelin
Ipamorelin
2
Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020.
10.1002/rco2.9
high
Growth hormone secretagogues: history, mechanism of action, and clinical development
kojic-acid
Kojic Acid
0
Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013;58(4):281-285.
10.4103/0019-5154.113940
high
Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety
kojic-acid
Kojic Acid
2
Saeedi M, Eslamifar M, Khezri K, et al. Review on the Use of Kojic Acid — A Skin-Lightening Ingredient. Cosmetics. 2022;9(3):64.
10.3390/cosmetics9030064
high
Review on the Use of Kojic Acid—A Skin-Lightening Ingredient
kojic-acid
Kojic Acid
3
Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9-13.
10.1111/j.1600-0536.1995.tb00832.x
high
Contact allergy to kojic acid in skin care products
larazotide
Larazotide (AT-1001, Larazotide Acetate)
0
Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021 (mechanism; zonulin/MLCK).
10.1152/ajpgi.00386.2020
high
Larazotide acetate: a pharmacological peptide approach to tight junction regulation
larazotide
Larazotide (AT-1001, Larazotide Acetate)
3
Fasano A, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000 (the zonulin concept). Porcine ischemia tight-junction repair (2021). (No FDA approval as of 2026; celiac program halted.)
10.1016/s0140-6736(00)02169-3
high
Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease
ll-37
LL-37 (Cathelicidin)
1
Lande R, et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. (LL-37 + self-DNA → TLR9/pDC); LL-37 as psoriasis T-cell autoantigen.
10.1002/eji.201344277
high
Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA
matrixyl
Matrixyl (Palmitoyl Pentapeptide-4)
0
Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. (anchor RCT, n=93)
10.1111/j.1467-2494.2005.00261.x
high
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin<sup>1</sup>
matrixyl
Matrixyl (Palmitoyl Pentapeptide-4)
1
Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000. (Sederma origin)
10.1046/j.1467-2494.2000.00010.x
high
Biologically active peptides: from a laboratory bench curiosity to a functional skin care product
melanotan-ii
Melanotan II
2
Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005.
10.1016/j.peptides.2005.01.023
high
Discovery that a melanocortin regulates sexual functions in male and female humans
mots-c
MOTS-c
0
Lee C, Zeng J, Drew BG, … Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. (discovery paper)
10.1016/j.cmet.2015.02.009
high
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
naringenin
Naringenin
0
Martinez RM, et al. Topical Formulation Containing Naringenin: Efficacy against Ultraviolet B Irradiation-Induced Skin Inflammation and Oxidative Stress in Mice. PLOS ONE. 2016.
10.1371/journal.pone.0146296
high
Topical Formulation Containing Naringenin: Efficacy against Ultraviolet B Irradiation-Induced Skin Inflammation and Oxidative Stress in Mice
naringenin
Naringenin
2
Kim HK, et al. Inhibitory effect of naringenin on LPS-induced skin senescence by SIRT1 regulation in HDFs. Biomedical Dermatology. 2018.
10.1186/s41702-018-0035-6
high
Inhibitory effect of naringenin on LPS-induced skin senescence by SIRT1 regulation in HDFs
naringenin
Naringenin
3
Martinez RM, et al. Protective Effects of Naringenin against UVB Irradiation and Air Pollution-Induced Skin Aging and Pigmentation. Cosmetics MDPI. 2023; 10(3):88.
10.3390/cosmetics10030088
high
Protective Effects of Naringenin against UVB Irradiation and Air Pollution-Induced Skin Aging and Pigmentation
niacinamide
Niacinamide (Vitamin B3)
0
Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002; 147(1):20-31.
10.1046/j.1365-2133.2002.04834.x
high
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer
niacinamide
Niacinamide (Vitamin B3)
1
Bissett DL, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004; 26(5):231-8.
10.1111/j.1467-2494.2004.00228.x
high
Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin<sup>1</sup>
niacinamide
Niacinamide (Vitamin B3)
3
Marques C, et al. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation. Antioxidants (Basel). 2021; PMC8389214.
10.3390/antiox10081315
high
Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation
niacinamide
Niacinamide (Vitamin B3)
5
Topical Niacinamide in Daily Skincare: A 3-Week Real-World Cosmetic Study. Appl Sci. 2025; 15(17):9729.
10.3390/app15179729
high
Topical Niacinamide in Daily Skincare: A 3-Week Real-World Cosmetic Study
noopept
Noopept (Omberacetam)
1
Ostrovskaya RU, et al. Noopept stimulates NGF and BDNF expression in rat hippocampus. Bull Exp Biol Med. 2008; (neuroprotection in an AD cellular model — apoptosis/tau). J Biomed Sci. 2014.
10.1007/s10517-008-0297-x
high
Noopept stimulates the expression of NGF and BDNF in rat hippocampus
pramlintide
Pramlintide (Symlin)
1
Cooper GJS, et al. Purification and characterization of a peptide from amyloid-rich pancreas of type-2 diabetics (amylin). PNAS. 1987 (discovery).
10.1073/pnas.84.23.8628
high
Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.
pramlintide
Pramlintide (Symlin)
4
Long-acting amylin-related peptides for obesity and T2D. (2026 review) — pramlintide as the first AMYR agonist, second-generation successors.
10.1016/j.peptides.2026.171480
high
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
pt-141
PT-141 (Bremelanotide)
0
Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005.
10.1016/j.peptides.2005.01.023
high
Discovery that a melanocortin regulates sexual functions in male and female humans
rapamycin
Rapamycin (Sirolimus)
0
Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009 (NIA ITP; 3-lab replication; late-life start; the field-defining result).
10.1038/nature08221
high
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
rapamycin
Rapamycin (Sirolimus)
3
Roark KM, Iffland PH. Rapamycin for longevity: pros, cons, future perspectives. Front Aging 2025; PEARL RCT (weekly dosing safety; longevity endpoints not met). (Approved immunosuppressant; longevity use off-label and unproven in humans as of 2026.)
10.3389/fragi.2025.1628187
high
Rapamycin for longevity: the pros, the cons, and future perspectives
retinol
Retinol (Vitamin A)
0
Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986; 15(4 Pt 2):836-59.
10.1016/s0190-9622(86)70242-9
high
Topical tretinoin for photoaged skin
retinol
Retinol (Vitamin A)
3
Kikuchi K, Suetake T, Kumasaka N, Tagami H. Improvement of photoaged facial skin in middle-aged Japanese females by topical retinol (vitamin A alcohol): a vehicle-controlled, double-blind study. J Dermatolog Treat. 2009; 20(5):276-81.
10.1080/09546630902973987
high
Improvement of photoaged facial skin in middle-aged Japanese females by topical retinol (vitamin A alcohol): A vehicle-controlled, double-blind study
retinol
Retinol (Vitamin A)
4
Draelos ZD, et al. A Double-Blind, Comparative Clinical Study of Newly Formulated Retinol Serums vs Tretinoin Cream in Escalating Doses. J Drugs Dermatol. 2020; 19(6):625-31. doi:10.36849/JDD.2020.5085.
10.36849/jdd.2020.5085
high
A Double-Blind, Comparative Clinical Study of Newly Formulated Retinol Serums vs Tretinoin Cream in Escalating Doses: A Method for Rapid Retinization With Minimized Irritation
retinol
Retinol (Vitamin A)
5
Zasada M, Budzisz E, Erkiert-Polguj A. A Clinical Anti-Ageing Comparative Study of 0.3 and 0.5% Retinol Serums. Skin Pharmacol Physiol. 2020; 33(2):102-116.
10.1159/000508168
high
A Clinical Anti-Ageing Comparative Study of 0.3 and 0.5% Retinol Serums: A Clinically Controlled Trial
retinol
Retinol (Vitamin A)
6
Motamedi M, Chehade A, Sanghera R, Grewal P. A Clinician's Guide to Topical Retinoids. J Cutan Med Surg. 2022; 26(1):71-78. doi:10.1177/12034754211035091.
10.1177/12034754211035091
high
A Clinician’s Guide to Topical Retinoids
retinol
Retinol (Vitamin A)
7
Siddiqui MA, Ali Z, Bilal M, et al. Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis. Sci Rep. 2025 (23 RCTs, n=3,905).
10.1038/s41598-025-12597-0
high
Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis
retinol
Retinol (Vitamin A)
8
Xie Y, et al. Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Dermatol Pract Concept. 2025 (8 RCTs, n=1,361; comparator context for retinol).
10.5826/dpc.1504a5172
high
Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials
retinol
Retinol (Vitamin A)
9
Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of Vitamin A (retinol, retinyl acetate, retinyl palmitate) in cosmetic products. SCCS/1639/21. European Commission.
10.1016/j.yrtph.2016.11.017
high
Opinion of the Scientific Committee on Consumer Safety (SCCS) – Final version of the Opinion on Vitamin A (retinol, retinyl acetate and retinyl palmitate) in cosmetic products
slu-pp-332
SLU-PP-332 (ERR agonist / "exercise mimetic")
0
Billon C, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. (the discovery/mechanism).
10.1021/acschembio.2c00720
high
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
slu-pp-915
SLU-PP-915
0
Billon C, Appourchaux K, Côté I, Burris TP. An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787 (the defining paper: oral activity, distinct scaffold, comparable efficacy at lower dose, Ddit4).
10.1016/j.jpet.2025.103787
high
An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
slu-pp-915
SLU-PP-915
1
Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024 (class metabolic effects).
10.1124/jpet.123.001733
high
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
squalane
Squalane
0
Kim SK, Karadeniz F. Biological importance and applications of squalene and squalane. Adv Food Nutr Res. 2012; 65:223-33.
10.1016/b978-0-12-416003-3.00014-7
high
Biological Importance and Applications of Squalene and Squalane
squalane
Squalane
1
Sethi A, Kaur T, Malhotra SK, Gambhir ML. Moisturizers: The Slippery Road. Indian J Dermatol. 2016; 61(3):279-87.
10.4103/0019-5154.182427
high
Moisturizers: The slippery road
squalane
Squalane
2
Pappas A. Epidermal surface lipids. Dermatoendocrinol. 2009; 1(2):72-76 (sebum squalene context).
10.4161/derm.1.2.7811
high
Epidermal surface lipids
squalane
Squalane
3
Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules. 2009; 14(1):540-54.
10.3390/molecules14010540
high
Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology
ss-31
SS-31 (Elamipretide)
3
Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal-muscle performance in aged mice. Aging Cell. 2013; Campbell MD, et al. Free Radic Biol Med. 2019.
10.1111/acel.12102
high
Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice
ss-31
SS-31 (Elamipretide)
4
Elamipretide mechanistic review — first cardiolipin-directed mitochondrial therapeutic approved under accelerated approval. Drug Discov Ther. 2026.
10.5582/ddt.2025.01111
high
Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval
survodutide
Survodutide (BI 456906)
2
Sanyal AJ, et al. A Phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311–319.
10.1056/nejmoa2401755
high
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
syn-ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
0
McArdle JJ, Lentz TL, Witzemann V, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999 (the toxin pharmacology behind it).
10.1016/s0022-3565(24)38167-4
high
Waglerin-1 Selectively Blocks the Epsilon Form of the Muscle Nicotinic Acetylcholine Receptor
syn-ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
2
Debono J, et al. Viper venom botox: the molecular origin and evolution of the waglerin peptides used in anti-wrinkle skin cream. J Mol Evol (biomimetic origin).
10.1007/s00239-016-9764-6
high
Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream
tb-500
TB-500 (Thymosin Beta-4 fragment)
0
Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. (Tβ4 biology review.)
10.1016/j.molmed.2005.07.004
high
Thymosin β: actin-sequestering protein moonlights to repair injured tissues
tb-500
TB-500 (Thymosin Beta-4 fragment)
3
Thymosin Beta-4 and TB-500 in tissue healing and musculoskeletal repair: a scoping review. Appl Sci. 2026.
10.20944/preprints202605.1124.v1
high
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
tesofensine
Tesofensine
0
Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-1913 (Phase 2; ~2× era's drugs; HR +~7 bpm).
10.1016/s0140-6736(08)61525-1
high
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
tesofensine
Tesofensine
2
Sjödin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite… Int J Obes 2010 (↑energy expenditure + ↓appetite; mechanism "unresolved").
10.1038/ijo.2010.87
high
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
End of preview. Expand in Data Studio

Vallydia Ingredient-Evidence Register

DOI License: CC BY 4.0

An open, evidence-graded reference dataset of 85 cosmetic and research ingredients — peptides, small molecules, proteins and blends — published by Vallydia under CC-BY-4.0.

Most ingredient databases tell you what a compound is. This one tells you how good the evidence actually is, outcome by outcome, and says so honestly when the answer is "we don't know" or "it was tested and it failed".

  • Per-outcome A–F evidence grades — a compound can be B for one outcome and F for another. 456 graded outcome rows.
  • DOI-verified citations — 117 citations resolved to a DOI with a verified title. This is the credibility spine of the dataset.
  • Machine-readable cosmetic-claims maps — for each cosmetic ingredient, the claims that may be made and the claims that must not be. 246 claim rows.
  • Legal status by region (INT / EU / US / UK) and WADA prohibited status.
  • Chemical identifiers — CAS, PubChem CID, InChIKey, SMILES — each with an explicit confidence level and provenance. Where no confident match exists, the field is blank on purpose.
  • Molecular structure images rendered from those identifiers, correct by construction.

Scope, and what is deliberately absent

This is an appearance-and-evidence reference. It contains no dosing, no administration or reconstitution information, and no commerce data — not in any field, and none is introduced by the generator. Research and injectable compounds (GLP-1 analogs, BPC-157, melanotan, and so on) are included as reference entries with their honest grades and legal status, never framed as usable or obtainable.

This is not medical advice. The grades are Vallydia's own evidence assessment, not third-party certification or peer review (reviewer_status is unassigned on every row, and we say so rather than implying a review that did not happen).

Dataset summary

Compounds 85
Classes peptide (53), small_molecule (23), blend (5), protein (3), polysaccharide (1)
Graded outcome rows 456 (97 intentionally ungraded — see below)
Cosmetic ingredients 21, with 246 permitted/forbidden claim rows
Legal-status rows 132
Cited sources 373, of which 117 are DOI-verified across 50 compounds
WADA-prohibited 19
Confident chemical identifiers 64 of 85 (21 honestly blank)
Structure images 42 2D structures + 22 large-molecule data cards

Supported tasks

Evidence-grade classification, evidence-grounded question answering, regulatory-claim checking (which claims are permissible for a given cosmetic ingredient), and retrieval-augmented generation over data/corpus.jsonl.

Languages

English (en).

Dataset structure

Canonical, lossless

  • data/compounds.jsonl — one JSON object per compound with the full nested structure, including the parsed Markdown body (body_sections) and a raw copy (body_markdown). This is the master file and the primary RAG-ingestion format.
  • data/compounds.json — the same content as a single JSON array.

Flat table

  • data/compounds.csv — one row per compound: scalar core plus |-joined lists, and best_outcome_grade / worst_outcome_grade computed over the non-null grades.

Long / tidy tables (the analytical heart)

  • data/grades.csv — one row per compound × outcome.
  • data/legal_status.csv — one row per compound × region.
  • data/citations.csv — the DOI provenance table, joined back to the source text.
  • data/cosmetic_claims.csv — permitted and forbidden claim wordings per cosmetic ingredient.
  • data/identifiers.csv — chemical identifiers with confidence and provenance.

Parquet mirrorsdata/parquet/*.parquet for all of the above (Hugging Face auto-generates Croissant JSON-LD from these).

Retrieval corpus

  • data/corpus.jsonl — one record per compound: {slug, name, title, url, text}, where text is a natural-language rendering of the identity, the per-outcome grades, the legal status and the caveats. Every record carries its https://vallydia.com/compound/<slug> URL so a citation resolves back to the source.

Imagesimages/structures/<slug>.svg (+ .png) and images/MANIFEST.csv, which carries mandatory factual alt_text for every image.

Full field-by-field documentation: DATA_DICTIONARY.md.

The grading scale

Two axes: consistency of evidence × magnitude/quality of effect.

Grade Meaning
A Strong, consistent human evidence
B Good human evidence, smaller or formulation-dependent effect
C Mixed or limited human evidence
D Weak — mechanistic or very small studies only
F Either untested/unproven, or tested and failed — two different meanings that share a letter
null The row is not an efficacy claim at all (safety and skin-penetration rows, for instance). Carried as null; never coerced into a letter.

Grades are assigned per outcome, not per compound. overall_grade reflects the leading, best-supported application, graded honestly downward and never up. See METHODOLOGY.md and vallydia.com/methodology.

Chemical identifiers, and why some are blank

Identifiers are resolved against PubChem by exact name/synonym match. A wrong identifier is worse than a blank one in an evidence dataset, so the rule is: no confident, unambiguous match → blank field and identifier_confidence: none. The 21 blanks are blends, stacks, multi-component biologics and proprietary analogs that have no single structure to point at. Where an ambiguity is real, it is recorded rather than resolved by guesswork — see entity_note in identifiers.csv (GHK-Cu is the live example: PubChem's record is the free tripeptide ligand, not the copper(II) complex, and the dataset and the image alt-text both say so).

Structure images are rendered only from high-confidence SMILES. Molecules too large for an honest 2D depiction (large peptides, GLP-1-class analogs) get a factual data card instead of an unreadable hairball.

Dataset creation

Curation rationale. Vallydia maintains an evidence-graded ingredient register because the cosmetic and research-compound market is dominated by claims that outrun their evidence. Publishing the register as open data is the most direct way to say: here is our evidence assessment — audit it.

Source data. Published literature synthesized by Vallydia into the compound register at vallydia.com. The dataset is generated from that register by build/generate_dataset.py — it is not hand-written, and re-running the generator on the same source reproduces it byte-for-byte.

Annotations. The A–F grades and the cosmetic-claims maps are produced by Vallydia. reviewer_status is unassigned throughout: no external reviewer has signed off, and the dataset does not pretend otherwise.

Considerations for using the data

  • Not medical advice, and not a dosing reference. Appearance and evidence context only.
  • Grades are an assessment, not a measurement. They encode a judgment about a literature base; reasonable experts may grade differently. The base, effect and caveat fields exist so you can check the reasoning rather than take the letter on faith.
  • Coverage bias. The register covers compounds Vallydia's audience actually asks about — cosmetic actives and popular research peptides. It is not a systematic sample of chemical space.
  • Literature bias. Grades inherit the biases of the published literature: small samples, industry-funded cosmetic trials, and publication bias toward positive findings. The caveat field records these where they are known.
  • Regulatory data ages. legal_status and status_note reflect the date in last_updated. Verify anything regulatory against the primary source before relying on it.

Usage

import pandas as pd

compounds = pd.read_parquet("data/parquet/compounds.parquet")
grades    = pd.read_parquet("data/parquet/grades.parquet")

# Cosmetic ingredients with at least one A-graded outcome
best = grades[grades.grade == "A"].merge(
    compounds[compounds.is_cosmetic][["slug", "name"]], on="slug"
)
from datasets import load_dataset
ds = load_dataset("vallydia/ingredient-evidence-register", "grades")

More in examples/.

License and attribution

CC-BY-4.0. You may use, remix and redistribute this data, including commercially, provided you give attribution.

Data: Vallydia Ingredient-Evidence Register (https://vallydia.com), CC-BY-4.0.

Citation

Cite the concept DOI — it always resolves to the latest version:

Bilenko, J. (2026). Vallydia Ingredient-Evidence Register (Version 1.0.0) [Data set]. Vallydia. https://doi.org/10.5281/zenodo.21364453

@dataset{vallydia_ingredient_evidence_register,
  title     = {Vallydia Ingredient-Evidence Register},
  author    = {Bilenko, Jacob},
  year      = {2026},
  publisher = {Vallydia},
  version   = {1.0.0},
  doi       = {10.5281/zenodo.21364453},
  url       = {https://vallydia.com},
  note      = {CC-BY-4.0}
}

Maintained by Vallydia · Methodology · Datasheet · Data dictionary

Downloads last month
18